Rani Therapeutics
RANI
15 hedge funds and large institutions have $19.6M invested in Rani Therapeutics in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
5.57% more ownership
Funds ownership: 0% → 5.57% (+5.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NFGH
Nan Fung Group Holdings
Kai Tak,
Hong Kong
|
+$8.54M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.9M |
| 3 |
CCM
CAAS Capital Management
New York
|
+$1.3M |
| 4 |
Goldman Sachs
New York
|
+$1.05M |
| 5 |
Squarepoint
New York
|
+$865K |
Top Sellers
RANI Hedge Fund Activity: Q3 2021 in Review
15 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Rani Therapeutics (RANI) for Q3 2021, worth a combined $19.6M.
Buyers outnumbered sellers: 15 funds opened new RANI positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Nan Fung Group Holdings, opening a new position worth an estimated $8.54M.
- 15 institutional investors held Rani Therapeutics (RANI) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $19.6M of Rani Therapeutics stock for Q3 2021.
- 15 funds opened new Rani Therapeutics positions in Q3 2021 and 0 closed out, a net change of +15 holders.
- The largest Rani Therapeutics buyer in Q3 2021 was Nan Fung Group Holdings, an estimated $8.54M added.
Based on aggregated 13F filings for Q3 2021.